

CLINICAL *Trials*



Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

AUGUST 2020

**SUBSCRIBE TO
KARMANOS CLINICAL TRIALS**

To view the current issue online, please [click here](#).



Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

| | | | |
|------------------------|-------------|----------------|----------|
| Bone Marrow Transplant | Gynecologic | Immunotherapy | Phase 1 |
| Breast | Head & Neck | Melanoma/Skin | Sarcoma |
| Gastrointestinal | Hematology | Neuro-Oncology | Thoracic |
| Genitourinary | | | |

Bone Marrow Clinical Trials

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

BONE MARROW TRANSPLANT

STUDY 2011-086

NA

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

STUDY 2018-145

Phase III

Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)

STUDY BMTCTN1506

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2020-004**Phase I/II**

A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 in Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Post Allogeneic Hematopoietic Cellular Transplantation (HCT)

STUDY 2019-125**Phase II**

A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs -NSCLC) Alone or in Combination with Pembrolizumab in Subjects with Advanced Unresectable or Metastatic NSCLC Previously Treated with Anti-PD-1

STUDY 2019-005**Phase III**

A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)

STUDY 2019-100**Phase III**

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

STUDY BMTCTN1703**Phase III**

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

STUDY 2018-084**Phase I/II**

A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

STUDY 2019-096**NA**

Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B-Cell Lymphoma Patients with Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

STUDY 2018-121**Phase I/II**

An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed and/or Refractory Multiple Myeloma

STUDY 2017-081**Phase III**

Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

STUDY 2014-103**Phase I/II**

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

STUDY A051301**Phase III**

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

STUDY 2016-209**Phase II**

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

STUDY 2019-106**NA**

Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells

INFECTIOUS DISEASE**2020-034****NA**

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

[RETURN TO TOP](#)

Breast Clinical Trials

For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ADJUVANT**STUDY NRG-BR003****Phase III**

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY NEW 2020-037**Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY A011502**Phase III**

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

ADJUVANT HORMONAL**STUDY 2017-129****NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

STUDY 2019-127**Phase II**

A Multinational, Multicenter, Phase 2 Study of Tese taxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane

ADJUVANT RADIATION

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

NEOADJUVANT**STUDY RTOG1304****Phase III**

NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

STUDY EA1131**Phase III**

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neo-adjuvant Chemotherapy

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADVANCED (STAGE IV) CHEMOTHERAPY**STUDY 2017-129****NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2019-079**Phase I/II**

A Phase 1/2, Open-Label, Dose-Escalation Study of ISB1302 in Subjects with HER2-Positive Metastatic Breast Cancer

STUDY NRG-BR004**Phase III**

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

STUDY 2018-054**Phase I**

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2019-043**Phase III**

Elacestrant Monotherapy VS. Standard of care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)

STUDY 2020-002**Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

HORMONAL**STUDY 2017-129****NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

STUDY NEW 2020-037**Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

OTHERS**STUDY NEW 2020-037****Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY A011401**Phase III**

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY NEW RTOG3510**Phase III**

Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

STUDY 2013-118**Phase I**

A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-positive Metastatic Breast Cancer.

STUDY 2019-079**Phase I/II**

A Phase 1/2, Open-Label, Dose-Escalation Study of ISB1302 in Subjects with HER2-Positive Metastatic Breast Cancer

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY A221702**NA**

ARM: Axillary Reverse Mapping- A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping

STUDY S1501**Phase III**

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer

STUDY 2018-141**Phase I/II**

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY 2017-073**Phase II**

The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with Early Stage Breast Cancer

Gastrointestinal Clinical Trials

For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ESOPHAGUS

Metastatic

STUDY 2019-008

Phase III

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

GASTRIC AND GASTROESOPHAGEAL JUNCTION

Metastatic

STUDY NEW 2018-088

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

STUDY 2016-037

Phase I/II

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2019-108

Phase I

A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

STUDY 2019-105

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Flucopyrimidine Versus Placebo plus Platinum and Flucopyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY 2017-087

Phase I

A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2016-037

Phase I/II

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2016-003

Phase I/II

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

PANCREAS

Adenocarcinoma

Locally Advanced Unresectable

STUDY 2018-048

Phase III

PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma

STUDY 2018-076

Phase I/II

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

Metastatic

STUDY 2018-046

Phase II/III

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred

STUDY 2018-076

Phase I/II

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2018-166

Phase I/II

A Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

STUDY 2019-002

Phase III

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY 2017-069

Phase I/II

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2019-088

Phase I/II

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

HCC

Adjuvant

STUDY 2019-048

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

STUDY RTOG1112

Phase III

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Phase III Therapy Followed By Sorafenib in Hepatocellular Carcinoma

BILIARY/GALL BLADDER

Metastatic

STUDY S1815

Phase III

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

STUDY 2019-003

Phase III

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial

STUDY 2014-081

Phase II

A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy

STUDY 2019-009

Phase III

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

COLON

Adjuvant

STUDY A021502**Phase III**

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair

Metastatic (Includes Rectal)**1st Line****STUDY 2019-108****Phase I**

A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

2nd Line**STUDY 2016-055****Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2019-108**Phase I**

A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

STUDY S1613**Phase II**

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2016-003**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2019-010**Phase III**

A Randomized, Multicenter, Parallel-Group, Phase III Study to Compare the Efficacy of Arfolitoxorin versus Leucovorin in Combination with 5-fluorouracil, Oxaliplatin, and Bevacizumab in Patients with Advanced Colorectal Cancer

STUDY A021703**Phase III**

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2019-088**Phase I/II**

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

STUDY NRG-GI005**Phase II/III**

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

RECTUM

STUDY 2017-129

NA

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY EA2165

Phase II

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

ANAL

Localized

STUDY EA2182

Phase II

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

STUDY EA2165

Phase II

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

NEUROENDOCRINE TUMORS AND CARCINOID

STUDY A021602

Phase III

Randomized, Double-Blind Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)

STUDY 2017-144

NA

Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using alpha-[11C]methyl-L-tryptophan (AMT)-PET

IMAGING STUDIES

Metastatic

STUDY NEW 2018-171

Phase II

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2006-127**NA**

Use of [F-18] FLT for Imaging with Positron Emission Tomography (PET)

[RETURN TO TOP](#)

Genitourinary Clinical Trials

For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

RENAL**STUDY EA8143****Phase III**

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

STUDY 2020-002**Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY 2019-084**Phase III**

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

STUDY 2017-082**Phase I/II**

A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients

STUDY 2017-111**Phase I**

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2016-003**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

PROSTATE**STUDY S1802****Phase III**

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

STUDY 2019-045**Phase II**

A Multicentre Phase IIb Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects with Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment with a Taxane

STUDY EA8153**Phase II**

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHARTED2 Trial

STUDY NRG-GU005**Phase III**

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

STUDY 2015-135**Phase II**

Phase II Trial of Immune Checkpoint Inhibitor Pembrolizumab with Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer

STUDY RTOG3506**Phase II**

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features

STUDY 2019-123**Phase I**

A Phase 1, Open-Label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients with Metastatic, Castration Resistant Prostate Adenocarcinoma

STUDY 2018-163**Phase I**

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

STUDY 2018-173**Phase III**

The MAP TRIAL: Phase III Study of Muscadine Plus (MPX) in Men with Prostate Cancer: A Randomized Double-Blind, Placebo-Controlled Study of the Effects of MPX Capsules on Rising Prostate-Specific Antigen Levels in Alanine/Alanine SOD2 Genotype Men Following Initial Therapy for Prostate Cancer

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2018-124**Phase I/II**

Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY 2017-126**Phase II**

Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

STUDY NRG-GU002**Phase II/III**

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

STUDY 2019-027**Phase II**

IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations

STUDY 2015-167**Phase II**

A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

STUDY 2013-108**NA**

Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer

STUDY 2017-156**Phase II**

Prospective Study of Apalutamide and Abiraterone Acetate in Chemotherapy naive men with mCRPC Stratified by Race (PANTHER)

STUDY 2019-007**Phase I/II**

A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)

BLADDER**STUDY 2020-002****Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY 2019-101**Phase I**

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY 2016-003**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2015-101**Phase I/II**

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in patients with BCG-naïve Non-Muscle Invasive Bladder Cancer

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-070**Phase II**

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin(BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

STUDY S1806**Phase III**

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

STUDY 2018-023**Phase I/II**

An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY 1163877) in Combination with Atezolizumab as First-line Treatment in Cisplatin-Ineligible Patients with FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2018-165**Phase III**

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)

STUDY 2018-044**Phase II**

Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

STUDY 2016-195**Phase II**

Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]

STUDY 2018-110**Phase II**

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

OTHER**STUDY NEW 2018-171****Phase II**

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

[RETURN TO TOP](#)

Gynecologic Clinical Trials

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

CERVIX**STUDY 2017-010****Phase II**

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

OVARY

STUDY 2018-141

Phase I/II

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY NRG-GY005

Phase II/III

Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib Alone or Olaparib Alone or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

STUDY GOG-3045

Phase III

A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced Highgrade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY 2018-054

Phase I

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY GOG-3018

Phase III

The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

STUDY 2016-037

Phase I/II

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2020-002

Phase I/II

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY NRG-GY019

Phase III

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

STUDY 2018-159

Phase II

Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

STUDY 2018-126

Phase II

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients with Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

UTERUS

STUDY 2018-141

Phase I/II

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

OTHER

STUDY 2018-054

Phase I

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY NRG-GY019

Phase III

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

STUDY 2018-126

Phase II

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients with Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

STUDY GOG-3031

Phase III

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY)

STUDY GOG-3045

Phase III

A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced Highgrade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

[RETURN TO TOP](#)

Head & Neck Clinical Trials

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

STAGES I/II/III

STUDY 2018-117

Phase II

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma(HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).

STUDY RTOG-1008

Phase II/III

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

STUDY 2019-069

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

STUDY NRG-HN001**Phase II/III**

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

STUDY EA3132**Phase II**

Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

STUDY EA3163**Phase II**

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

STUDY 2017-157**Phase III**

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

STUDY EA3161**Phase II/III**

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

ANY STAGE**STUDY 2017-069****Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2019-087**Phase I**

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients with HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

STUDY 2020-006**Phase III**

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Clinical Study of Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010)

STUDY 2019-099**Phase II**

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer

STUDY 2016-212**Phase II**

A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

OTHER

STUDY NRG-HN005**Phase II/III**

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2017-087**Phase I**

A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2019-101**Phase I**

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY NEW 2018-171**Phase II**

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

[RETURN TO TOP](#)

Hematology Clinical Trials

For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

MULTIPLE MYELOMA**STUDY 2019-006****Phase I/II**

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

STUDY 2019-071**Phase I/II**

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

STUDY 2018-042**Phase III**

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14) Positive Relapsed or Refractory Multiple Myeloma

STUDY S1803**Phase III**

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration

(DRAMMATIC Study)

STUDY NEW 2017-136

Phase I

An Open-label, Phase II Pilot Study of Dabrafenib and/or Trametinib in Patients with Relapsed and/or Refractory Multiple Myeloma

STUDY 2018-014

Phase I

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

STUDY 2018-176

Phase I/II

MyDRUG: Myeloma-Developing Regimens Using Genomics (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination with a Backbone Regimen)

STUDY 2019-054

Phase II

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment

STUDY 2012-122

Phase I/II

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma

STUDY NEW 2019-116

Phase I/II

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)

STUDY 2014-090

Phase I

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

STUDY 2016-086

Phase I/II

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

STUDY 2019-014

Phase II

Open-label, Single-arm, Phase 2 Study of Initial Treatment with Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy.

STUDY 2018-112

Phase I

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

AMYLOIDOSIS OR LIGHT CHAIN DEPOSITION DISEASE

STUDY 2019-146**Phase III**

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)

STUDY 2020-007**Phase II**

A Phase 2, Open-Label, Multicenter Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients with AL Amyloidosis

STUDY 2016-200**Phase II**

An Open Label, Multicenter, Phase 2 Trial of Lenalidomide /Dexamethasone/ Elotuzumab, Followed by Lenalidomide/Dexamethasone/Elotuzumab Maintenance After at Least One Line of Therapy for Patients with Relapsed AL Amyloidosis (CA204-192)

STUDY 2016-060**Phase I**

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects with Relapsed or Refractory AML

STUDY NEW 2020-037**Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

LEUKEMIA**Acute Myeloid Leukemia (AML)****STUDY 2017-120****Phase III**

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

STUDY 2017-119**Phase III**

Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects \leq 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

STUDY 2019-023**Phase I**

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

STUDY 2018-027**Phase I/II**

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy

STUDY BMTCTN1506**Phase III**

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2019-111**Phase III**

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia (CLL)

STUDY 2019-103

Phase II

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax (Phase 2)

STUDY 2019-110

Phase II

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) in Subjects With Chronic Lymphocytic Leukemia (CLL)

STUDY 2014-132

Phase III

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

LYMPHOMA

Hodgkin's

STUDY 2016-033

Phase II

A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma

STUDY 2019-074

Phase II

A Phase 2, Multicenter, Single-arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

STUDY 2019-102

Phase II

A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T Cell Lymphoma (PTCL) In Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy

STUDY S1826

Phase III

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

STUDY 2017-132

Phase II

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Non-Hodgkin's

Aggressive (Mantle Cell, Large B-Cell Lymphoma)

STUDY 2017-025

Phase III

Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma

STUDY 2013-047

Phase I

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2014-132**Phase III**

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

STUDY EA4181**Phase II**

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients greater than or equal to 70 years old with Untreated Mantle Cell Lymphoma

STUDY 2018-094**Phase I/II**

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (BTCT4465A) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

T cell**STUDY 2019-102****Phase II**

A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T Cell Lymphoma (PTCL) In Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy

STUDY 2016-056**Phase II**

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

STUDY 2019-074**Phase II**

A Phase 2, Multicenter, Single-arm Study of Retreatment with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T Cell Lymphoma (PTCL)

STUDY 2016-125**Phase I/II**

A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in B Cell Non Hodgkin's Lymphoma

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2019-115**Phase III**

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY NEW 2020-037**Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY 2018-003**Phase I**

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma
Jeffrey Zonder, M.D.

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

MYELODYSPLASTIC SYNDROME (MDS)**STUDY 2018-027****Phase I/II**

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy

STUDY 2019-023**Phase I**

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

OTHER**STUDY 2019-100****Phase III**

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

STUDY 2019-057**Phase II**

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy- Requiring Polycythemia Vera

STUDY 2013-113**Phase II**

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI- 32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

[RETURN TO TOP](#)

Immunotherapy Clinical Trials

For more information on Immunotherapy Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

IMMUNOTHERAPY**STUDY 2018-015****Phase I/II**

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

[RETURN TO TOP](#)

Melanoma/Skin Clinical Trials

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ADVANCED

STUDY 2020-002

Phase I/II

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY EA6134

Phase III

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

STUDY NEW 2020-019

Phase I/II

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

STUDY 2016-037

Phase I/II

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2013-047

Phase I

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2017-069

Phase I/II

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-087

Phase I

A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

OTHER

STUDY 2016-055

Phase I

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

[RETURN TO TOP](#)

Neuro-Oncology Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

[RETURN TO TOP](#)

Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

ALL SOLID TUMORS

STUDY 2016-037

Phase I/II

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2017-087

Phase I

A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2018-076

Phase I/II

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2018-157

Phase I

An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas

STUDY 2020-002

Phase I/II

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY 2018-034

Phase I

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-111

Phase I

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

STUDY NEW 2020-019

Phase I/II

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

STUDY 2019-082

Phase I

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

STUDY 2018-066

Phase I

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb@20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

STUDY 2018-035**Phase I**

A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

STUDY NEW 2018-100**Phase I**

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies

STUDY 2018-054**Phase I**

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2019-098**Phase I/II**

A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

STUDY 2018-156**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)

STUDY 2018-158**Phase I/II**

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

STUDY 2018-104**Phase I/II**

A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies

STUDY 2017-052**Phase I**

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

STUDY 2017-088**Phase I**

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

TUMOR SPECIFIC**STUDY 2018-076****Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY 2019-079**Phase I/II**

A Phase 1/2, Open-Label, Dose-Escalation Study of ISB1302 in Subjects with HER2-Positive Metastatic Breast Cancer

STUDY 2019-142**Phase I/II**

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)

STUDY 2013-047

Phase I

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2018-120**Phase I/II**

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2019-026**Phase I**

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

STUDY 2016-037**Phase I/II**

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2013-118**Phase I**

A Phase 1, Open-label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-positive Metastatic Breast Cancer.

STUDY 2016-055**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2017-069**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2018-166**Phase I/II**

A Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

STUDY 2019-023**Phase I**

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

STUDY 2019-007**Phase I/II**

A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)

STUDY 2019-070**Phase I**

Phase 1 Study of KN026 in HER2 Expressing Breast Cancer, Gastric/Gastroesophageal Junction Cancer and other Locally Advanced/Metastatic Solid Tumors

STUDY 2019-101**Phase I**

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY 2018-138**Phase I/II**

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinumpretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

STUDY 2019-053**Phase I**

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ- 61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

STUDY 2018-157**Phase I**

An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-981 in Adult Patients With Metastatic Solid Tumors or Lymphomas

STUDY 2018-141**Phase I/II**

A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer

STUDY 2019-123**Phase I**

A Phase 1, Open-Label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients with Metastatic, Castration Resistant Prostate Adenocarcinoma

STUDY 2019-071**Phase I/II**

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

STUDY 2019-088**Phase I/II**

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

STUDY 2018-163**Phase I**

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

GENOMIC TESTING SPECIFIC**STUDY 2018-054****Phase I**

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

[RETURN TO TOP](#)

Sarcoma Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

[RETURN TO TOP](#)

Thoracic Clinical Trials

For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

ADJUVANT

STUDY 2018-142

Phase III

A Phase III, Double-blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or SELECT IIIB Non-Small Cell Lung Cancer

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

MAINTENANCE

STUDY NRG-LU002

Phase II/III

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

STAGE I/II

STUDY 2019-142

Phase I/II

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)

STUDY 2019-053

Phase I

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ- 61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

STUDY 2019-018

Phase II

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

STUDY 2020-002

Phase I/II

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY NEW 2020-019

Phase I/II

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

STAGE III A/B

STUDY NEW 2020-019

Phase I/II

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

STUDY NEW 2020-037

Phase II

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard

Available Treatment for the
Treatment of COVID-19 in Patients with Cancer

STUDY 2018-060

Phase II

A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2019-034

Phase III

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-Line Treatment of Metastatic Squamous Non- Small Cell Lung Cancer (NSCLC)

STUDY 2018-120

Phase I/II

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2019-036

Phase III

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer

STUDY 2019-020

Phase III

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

STUDY 2018-065

Phase II

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients with Solid Tumors

STUDY 2017-152

Phase II

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

STUDY 2019-142

Phase I/II

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)

STUDY 2018-111

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

STUDY 2020-002

Phase I/II

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STAGE IV

ALK

STUDY 2019-142

Phase I/II

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)

EGFR

STUDY 2017-145

Phase II

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

STUDY 2019-142

Phase I/II

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)

Other Genetic Marker

STUDY 2014-002

Phase II

A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.

STUDY 2016-037

Phase I/II

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1

STUDY 2018-053

Phase III

METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

STUDY 2019-121

Phase I/II

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

STUDY 2017-145

Phase II

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

STUDY 2018-060

Phase II

A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-120

Phase I/II

An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2016-055

Phase I

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2017-111

Phase I

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2019-101

Phase I

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

STUDY NEW 2020-019**Phase I/II**

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

STUDY 2017-129**NA**

Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2015-174**NA**

Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging with Positron Emission Tomography (PET)

STUDY 2018-065**Phase II**

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

STUDY 2020-002**Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

RECURRENT**ALK****STUDY 2017-106****Phase II**

Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR**STUDY 2017-106****Phase II**

Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

STUDY 2020-002**Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

STUDY 2018-065**Phase II**

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

STUDY NEW 2020-019**Phase I/II**

A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors

SCLC LIMITED**STUDY NRG-LU005****Phase I/II**

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

STUDY 2020-002**Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

SCLC EXTENSIVE**STUDY 2020-002****Phase I/II**

A Phase 1/2 Study of ZN-C3 As A Single Agent And In Combination With Talazoparib or Pembrolizumab In Patients With Solid Tumors

MESOTHELIOMA**STUDY 2018-105****Phase II**

Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma

STUDY NEW 2020-037**Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

SARCOMA**STUDY NEW 2020-037****Phase II**

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer

OTHER**STUDY 2017-069****Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-087**Phase I**

A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2019-088**Phase I/II**

A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations

STUDY 2018-076**Phase I/II**

A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas

STUDY NEW 2018-171**Phase II**

A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2019-032**Phase III**

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy

STUDY 2018-081

Phase I

A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations

[RETURN TO TOP](#)

Karmanos Cancer Institute
4100 John R
Detroit, Michigan 48201
1-800-KARMANOS
(1-800-527-6266)
karmanos.org

To refer a patient or for more information on open clinical trials at the Karmanos Cancer Institute, call **1-800-Karmanos** (1-800-527-6266)

To schedule an appointment, please call between 7:30 AM – 5:30 PM, Monday – Friday

[FORWARD TO A COLLEAGUE](#)

[SUBSCRIBE TO KARMANOS CLINICAL TRIALS](#)



©2016 Karmanos Cancer Institute

This email was sent to alphacat68@gmail.com. To ensure that you continue receiving our emails, please add us to your address book or safe list.

[manage](#) your preferences | [opt out](#) using TrueRemove®.

Got this as a forward? [Sign up](#) to receive our future emails.